Organization | Fonds NutsOhra

Fonds NutsOhra Report issue

Foundation Phase 1 Phase 3 Phase 4

Founded: Amsterdam Netherlands (1999)

Organization Overview

First Clinical Trial

2004

NCT00230061

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2014

Timeline

NOW

Now

Alternative names

FondsNutsOhra | Fonds Nuts Ohra | Stichting Nuts Ohra

Active Ingredients

Drugs in Phase 4 Trials (4)

cilastatin (primaxin) (1 trial)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

imipenem (primaxin) (1 trial)

meropenem (merrem) (1 trial)

Drugs in Phase 3 Trials (4)

acetylcysteine (mucomyst) (1 trial)

acetylsalicylic acid (aspirin) (1 trial)

tranexamic acid (cyklokapron) (1 trial)

valganciclovir (Valcyte) (2 trials)

Drugs in Phase 1 Trials (1)

propofol (diprivan) (1 trial)

Drugs in Other Trials (1)

ceftriaxone (rocephin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia, Sickle Cell (Phase 3)

Colonic Neoplasms (Phase 3)

Cytomegalovirus Infections (Phase 3)

Deafness (Phase 3)

Febrile Neutropenia (Phase 4)

Fever (Phase 4)

Hearing Loss (Phase 3)

Hearing Loss, Sensorineural (Phase 3)

Hemorrhage (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Neutropenia (Phase 4)

Premature Birth (Phase 1)

Recurrence (Phase 3)

Subarachnoid Hemorrhage (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial APIs: 10